David Gius receives UT System award to advance research on aging and breast cancer
David Gius, MD, PhD, has been awarded a $1.6 million UT System Faculty STARs award to support his research on aging and breast cancer.
David Gius, MD, PhD, has been awarded a $1.6 million UT System Faculty STARs award to support his research on aging and breast cancer.
Shaun K. Olsen, PhD, has been awarded a $1 million UT System Faculty STARs award to conduct innovative research to better understand the molecular mechanisms of diseases and advance drug discovery efforts for treatment.
Cancer research at UT Health San Antonio is getting a $23 million boost from the Cancer Prevention and Research Institute of Texas (CPRIT).
USA Paralympics sitting volleyball player Jillian Williams, who beat Ewing sarcoma with help from San Antonio and Houston medical teams, is going for the gold in the Tokyo Paralympics.
In a U.S. and Swiss study, nearly all patients with cancer developed good immune response to the COVID-19 mRNA vaccines three to four weeks after receiving their second dose, but the fact that a small group of the patients exhibited no response raised questions about how their protection against the virus will be addressed moving forward.
The Mays Cancer Center, home to UT Health San Antonio MD Anderson, was named a founding partner of the Advancing Inclusive Research® Site Alliance.
The COVID-19 pandemic has interrupted delivery of key health services for children and adolescents, including HPV vaccination for cancer prevention.
Physicians with the Mays Cancer Center, home to UT Health San Antonio MD Anderson, praised the May 18 move by the U.S. Preventive Services Task Force to lower from 50 to 45 the recommended age to begin screening asymptomatic persons to prevent colorectal cancer. The goal is to identify and remove precancerous benign polyps. Physicians nationwide adhere to the panel’s guidelines.
This first-of-its-kind national cohort study will unpack the social, cultural, behavioral, psychosocial, biological and medical influences on post-cancer life in Latino cancer survivors to fill a crucial gap in knowledge about their survivorship experience.
According to the study, 53.4% of participants receiving NF were free of cancer at three months and 45.5% of patients continued to be cancer-free for at least 12 months.